丁型肝炎抗病毒治疗药物的研究进展

王彦; 张福杰

doi:10.3969/j.issn.1001-5256.2023.04.007

丁型肝炎抗病毒治疗药物的研究进展

DOI: 10.3969/j.issn.1001-5256.2023.04.007

王彦,
张福杰^, ,

首都医科大学附属地坛医院感染科，北京 100102

基金项目:

美国庄马尔田基金会 (2017-G14)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：王彦负责查阅和收集资料，撰写论文；张福杰负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
张福杰，treatment@chinaaids.cn (ORCID: 0000-0001-6386-9879)

计量
- 文章访问数: 392
- HTML全文浏览量: 74
- PDF下载量: 84
- 被引次数: 0
出版历程
- 收稿日期: 2022-10-08
- 录用日期: 2022-11-08
- 出版日期: 2023-04-20

Research advances in antiviral drugs for the treatment of hepatitis D

Yan WANG,
Fujie ZHANG^{,
,}

Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100102, China

Research funding:

John C. Martin Foundation (2017-G14)

More Information

Corresponding author: ZHANG Fujie, treatment@chinaaids.cn (ORCID: 0000-0001-6386-9879)

摘要

摘要: 丁型肝炎病毒(HDV)是一种乙型肝炎病毒(HBV)的卫星病毒，需借助HBV包膜蛋白完成自身的组装和复制，进而建立新的感染。慢性HDV感染是病毒性肝炎最严重的形式，可加速疾病进展，提高肝癌的发生风险，HDV感染者迫切需要有效的抗病毒治疗以缓解疾病进展，但能够用于抗HDV感染的治疗药物仅包括2020年7月欧洲药品管理局有条件批准的Bulevirtide以及之前推荐使用的干扰素。目前，针对病毒复制周期的几种靶向抗病毒药物正在研究中，且前期临床试验结果表现良好。这意味着HDV的抗病毒药物研发取得了重要突破，为丁型肝炎的治疗带来了希望。本文就目前丁型肝炎抗病毒药物进行简要综述，并对相关的治疗方案进行了讨论，为丁型肝炎的治疗提供参考。
- δ肝炎病毒 /
- 病毒复制 /
- 抗病毒药 /
- 药物疗法
Abstract: Hepatitis D virus (HDV) is a satellite virus of hepatitis B virus (HBV) and needs the help of HBV envelope protein to complete its own assembly and replication and then establish a new infection cycle. Chronic HDV infection is considered the most severe form of viral hepatitis, which can accelerate disease progression and increase the risk of liver cancer. Effective antiviral therapy is urgently needed to delay disease progression in patients with HDV infection, but Bulevirtide conditionally approved by European Medicines Agency in July 2020 and interferon previously recommended are the only drugs used for the treatment of HDV infection. At present, studies are being conducted for several antiviral drugs targeting viral replication cycle, and early clinical trials have obtained good results. This means that important breakthroughs have been made in the development of antiviral drugs, bringing hope for the treatment of hepatitis D. This article summarizes the current antiviral drugs for hepatitis D and discusses related treatment regimens, so as to provide a reference for the treatment of hepatitis D.
- Hepatitis Delta Virus /
- Virus Replication /
- Antiviral Agents /
- Drug Therapy

HTML全文

图 1 HDV的病毒复制过程

Figure 1. HDV life cycle

下载: 全尺寸图片幻灯片

表 1 慢性HDV感染的抗病毒药物临床试验

Table 1. Summary of clinical trials of antiviral agents for HDV infection

药物靶向	药物名称	研究阶段	治疗策略	状态
免疫调节	PEG-IFNα-2a	Phase 2	PEG-IFNα 180 mg/周，治疗3年	已完成
	PEG-IFNα-2a	Phase 2	PEG-IFNα-2a单药治疗48周；PEG-IFNα-2a联合Ribavirin治疗48周	已完成
	PEG-IFNα-2a	Phase 2	PEG-IFNα-2a 180 μg/周，联合安慰剂； PEG-IFNα-2a 180 μg/周，联合Tenofovir disoproxilfumar 245 mg/d	已完成
	PEG-IFNα-2a	Phase 3	PEG-IFNα-2a单药治疗48周，随访24周	已完成
	PEG-IFNα-2a	Phase 3	PEG-IFNα-2a 180 mg/周，治疗96周； Tenofovir 245 mg/d，治疗96周；安慰剂治疗96周	已完成
	PEG-IFNα-2b	Phase 3	PEG-IFNα-2b每周1.5 mg/kg，治疗52周	已完成
	PEG-IFNλ	Phase 2	PEG-IFNλ 180 μg/周，每周1次，治疗48周；PEG-IFNλ 120 μg/周，每周1次，治疗48周	已完成
	PEG-IFNλ	Phase 3	PEG-IFNλ 180 mg/周，每周1次，治疗48周然后随访24周；不处理12周后PEG-IFNλ 180 mg/周，每周1次，治疗48周然后随访24周	进行中
	Ropeginterferon alfa-2b	Phase 1	Ropeginterferon alfa-2b，Nivolumab和Entecavir联合用药	进行中
进入抑制剂	Myrcludex B	Phase 1和2	Myrcludex B 2 mg/d，治疗24周，然后PEG-IFNα-2a每周180 μg/0.5 mL，治疗48周；Myrcludex B 2 mg/d联合PEG-IFNα-2a每周180 μg/0.5 mL治疗24周，然后PEG-IFNα-2a每周180 μg/0.5 mL治疗24周；PEG-IFNα-2a每周180 μg/0.5 mL治疗48周	已完成
	Myrcludex B	Phase 2	Myrcludex B 2 mg/d，治疗24周，然后Tenofovir治疗24周；Myrcludex B 5 mg/d，治疗24周，然后Tenofovir治疗24周；Tenofovir单药治疗48周	已完成
	Bulevirtide	Phase 2	PEG-IFNα 180 mg/周，治疗48周；Bulevirtide 2 mg/d联合PEG-IFNα 180 mg/周，治疗48周，然后Bulevirtide 2 mg/d单药治疗48周；Bulevirtide 10 mg/d联合PEG-IFNα 180 mg/周，治疗48周，然后Bulevirtide 10 mg/d单药治疗48周；Bulevirtide 10 mg/d单药治疗96周	进行中
	Bulevirtide	Phase 3	观察48周后Bulevirtide 10 mg/d治疗96周；立即采用Bulevirtide 2 mg/d治疗144周；立即采用Bulevirtide 10 mg/d治疗144周	进行中
异戊烯化(法尼基化)抑制剂	Lonafarnib	Phase 2	Lonafarnib 100 mg；Lonafarnib 200 mg；安慰剂	已完成
	Lonafarnib	Phase 2	Lonafarnib 200 mg/d，每日2次；Lonafarnib 300 mg/d，每日2次；Lonafarnib 100 mg/d，每日3次； Lonafarnib 100 mg/d，每日2次，联合PEG-IFNα 180 μg/周，每周1次；Lonafarnib 200 mg/d，每日2次，联合PEG-IFNα 180 μg/周，每周1次；Lonafarnib 300 mg/d，每日2次，联合PEG-IFNα 180 μg/周，每周1次；Lonafarnib 100 mg/d，每日2次，联合Ritonavir 100 mg/d，每日1次	已完成
	Lonafarnib	Phase 2	Lonafarnib 100 mg/d，每日2次，联合Ritonavir 100 mg/d，每日1次；Lonafarnib 150 mg/d，每日1次，联合Ritonavir 100 mg/d，每日1次；Lonafarnib 75 mg/d，每日2次，联合Ritonavir 100 mg/d，每日2次，第12周联合PEG-IFNα 180 μg/周，每周1次；Lonafarnib 50 mg/d，每日2次，联合Ritonavir 100 mg/d，每日2次，第12周联合PEG-IFNα 180 μg/周，每周1次；Lonafarnib 100 mg/d，每日2次，联合Ritonavir 50 mg/d，每日2次；Lonafarnib 100 mg/d，每日1次，联合Ritonavir 100 mg/d，每日1次；Lonafarnib 50 mg/d，每日2次，联合Ritonavir 100 mg/d，每日2次；联合PEG-IFNα 180 μg/周，每周1次；Lonafarnib 25 mg/d，每日2次，联合Ritonavir 100 mg/d，每日2次，联合PEG-IFNα 180 μg/周，每周1次；Lonafarnib 50 mg/d，每日2次，联合Ritonavir 100 mg/d，每日2次；Lonafarnib 25 mg/d，每日2次，联合Ritonavir 100 mg/d，每日2次	已完成
	Lonafarnib	Phase 2	Lonafarnib 50 mg/d，每日2次，联合Ritonavir 100 mg/d，每日2次，然后Lonafarnib 75 mg/d，每日2次，最后提高到100 mg/d，每日2次，治疗6个月，随访6个月	已完成
	Lonafarnib	Phase 2	Lonafarnib(50 mg/d)和Ritonavir(100 mg/d)治疗24周；Lonafarnib(75 mg/d)和Ritonavir(100 mg/d)治疗24周；Lonafarnib(100 mg/d)和Ritonavir(100 mg/d)治疗24周；安慰剂治疗12周，然后Lonafarnib(50 mg/d)和Ritonavir(100 mg/d)治疗12周；安慰剂治疗12周，然后Lonafarnib(75 mg/d)和Ritonavir(100 mg/d)治疗12周；安慰剂治疗12周，然后Lonafarnib(100 mg/d)和Ritonavir(100 mg/d)治疗12周	已完成
	Lonafarnib	Phase 2	Lonafarnib, Ritonavir和PEG-IFNλ联合用药	已完成
	Lonafarnib	Phase 3	Lonafarnib 50 mg/d，每日2次，联合Ritonavir 100 mg/d，每日2次；Lonafarnib 50 mg/d，每日2次，联合Ritonavir 100 mg/d，每日2次+PEG-IFNα-2a 180 μg/周；Lonafarnib安慰剂和Ritonavir安慰剂联合PEG-IFNα-2a 180 μg/周；Lonafarnib安慰剂和Ritonavir安慰剂	进行中
核酸聚合物	REP 2139-Ca	Phase 2	REP 2139-Ca 500 mg/周，治疗15周，然后REP 2139-Ca 250 mg/周联合PEG-IFNα-2a 180 μg/周，治疗15周，之后PEG-IFNα-2a 180 μg/周，治疗33周	已完成
RNA干扰	JNJ-3989	Phase 2	治疗组：JNJ-73763989每4周皮下注射1次，联合核苷酸类似物治疗144周对照组：安慰剂联合核苷酸类似物治疗52周，然后JNJ-73763989每4周皮下注射1次，联合核苷酸类似物治疗96周	进行中
注：信息收集截止于2021年11月11日。

下载: 导出CSV

参考文献(55)

[1]	RIZZETTO M, CANESE MG, ARICÒ S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers[J]. Gut, 1977, 18(12): 997-1003. DOI: 10.1136/gut.18.12.997.
[2]	GILMAN C, HELLER T, KOH C. Chronic hepatitis delta: A state-of-the-art review and new therapies[J]. World J Gastroenterol, 2019, 25(32): 4580-4597. DOI: 10.3748/wjg.v25.i32.4580.
[3]	LUCIFORA J, DELPHIN M. Current knowledge on Hepatitis Delta Virus replication[J]. Antiviral Res, 2020, 179: 104812. DOI: 10.1016/j.antiviral.2020.104812.
[4]	TAYLOR JM. Infection by hepatitis delta virus[J]. Viruses, 2020, 12(6): 648. DOI: 10.3390/v12060648.
[5]	ALFAIATE D, CLÉMENT S, GOMES D, et al. Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies[J]. J Hepatol, 2020, 73(3): 533-539. DOI: 10.1016/j.jhep.2020.02.030.
[6]	KOH C, HELLER T, GLENN JS. Pathogenesis of and new therapies for hepatitis D[J]. Gastroenterology, 2019, 156(2): 461-476. DOI: 10.1053/j.gastro.2018.09.058.
[7]	WRANKE A, SERRANO BC, HEIDRICH B, et al. Antiviral treatment and liver-related complications in hepatitis delta[J]. Hepatology, 2017, 65(2): 414-425. DOI: 10.1002/hep.28876.
[8]	NEGRO F. Hepatitis D virus coinfection and superinfection[J]. Cold Spring Harb Perspect Med, 2014, 4(11): a021550. DOI: 10.1101/cshperspect.a021550.
[9]	CAREDDA F, ROSSI E, D'ARMINIO MONFORTE A, et al. Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome[J]. J Infect Dis, 1985, 151(5): 925-928. DOI: 10.1093/infdis/151.5.925.
[10]	KIESSLICH D, CRISPIM MA, SANTOS C, et al. Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus[J]. J Infect Dis, 2009, 199(11): 1608-1611. DOI: 10.1086/598955.
[11]	SMEDILE A, FARCI P, VERME G, et al. Influence of delta infection on severity of hepatitis B[J]. Lancet, 1982, 2(8305): 945-947. DOI: 10.1016/s0140-6736(82)90156-8.
[12]	TAYLOR JM. Virology of hepatitis D virus[J]. Semin Liver Dis, 2012, 32(3): 195-200. DOI: 10.1055/s-0032-1323623.
[13]	GIERSCH K, HELBIG M, VOLZ T, et al. Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection[J]. J Hepatol, 2014, 60(3): 538-544. DOI: 10.1016/j.jhep.2013.11.010.
[14]	CHEMIN I, PUJOL FH, SCHOLTÈS C, et al. Preliminary evidence for hepatitis delta virus exposure in patients who are apparently not infected with hepatitis B virus[J]. Hepatology, 2021, 73(2): 861-864. DOI: 10.1002/hep.31453.
[15]	GIERSCH K, ALLWEISS L, VOLZ T, et al. Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection[J]. J Hepatol, 2015, 63(2): 346-353. DOI: 10.1016/j.jhep.2015.03.011.
[16]	SANDMANN L, CORNBERG M. Experimental drugs for the treatment of hepatitis D[J]. J Exp Pharmacol, 2021, 13: 461-468. DOI: 10.2147/JEP.S235550.
[17]	CASEY JL. Control of ADAR1 editing of hepatitis delta virus RNAs[J]. Curr Top Microbiol Immunol, 2012, 353: 123-143. DOI: 10.1007/82_2011_146.
[18]	CHEN R, LINNSTAEDT SD, CASEY JL. RNA editing and its control in hepatitis delta virus replication[J]. Viruses, 2010, 2(1): 131-146. DOI: 10.3390/v2010131.
[19]	YURDAYDIN C, KESKIN O, KALKAN Ç, et al. Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease[J]. J Infect Dis, 2018, 217(8): 1184-1192. DOI: 10.1093/infdis/jix656.
[20]	SAGNELLI C, SAGNELLI E, RUSSO A, et al. HBV/HDV co-infection: epidemiological and clinical changes, recent knowledge and future challenges[J]. Life (Basel), 2021, 11(2): 169. DOI: 10.3390/life11020169.
[21]	KANG C, SYED YY. Bulevirtide: first approval[J]. Drugs, 2020, 80(15): 1601-1605. DOI: 10.1007/s40265-020-01400-1.
[22]	WEDEMEYER H, YURDAYDIN C, HARDTKE S, et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-Ⅱ): a randomised, placebo controlled, phase 2 trial[J]. Lancet Infect Dis, 2019, 19(3): 275-286. DOI: 10.1016/S1473-3099(18)30663-7.
[23]	WEDEMEYER H, YURDAYDÌN C, DALEKOS GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta[J]. N Engl J Med, 2011, 364(4): 322-331. DOI: 10.1056/NEJMoa0912696.
[24]	HEIDRICH B, YURDAYD₁N C, KABAÇAM G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta[J]. Hepatology, 2014, 60(1): 87-97. DOI: 10.1002/hep.27102.
[25]	LAZEAR HM, SCHOGGINS JW, DIAMOND MS. Shared and distinct functions of type Ⅰ and type Ⅲ interferons[J]. Immunity, 2019, 50(4): 907-923. DOI: 10.1016/j.immuni.2019.03.025.
[26]	CHAN H, AHN SH, CHANG TT, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)[J]. J Hepatol, 2016, 64(5): 1011-1019. DOI: 10.1016/j.jhep.2015.12.018.
[27]	ETZION O, HAMID S, LURIE Y, et al. End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection[J]. J Hepatol, 2019, 70(Suppl 1): e32.
[28]	KOH C, HERCUN J, RAHMAN F, et al. A phase 2 study of peginterferon lambda, lonafarnib and ritonavir for 24 weeks: end-of-treatment results from the LIFT HDV study[J]. J Hepatol, 2020, 73(Suppl 1): S130.
[29]	NKONGOLO S, NI Y, LEMPP FA, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor[J]. J Hepatol, 2014, 60(4): 723-731. DOI: 10.1016/j.jhep.2013.11.022.
[30]	BLANCHET M, SUREAU C, LABONTÉ P. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle[J]. Antiviral Res, 2014, 106: 111-115. DOI: 10.1016/j.antiviral.2014.03.017.
[31]	ABBAS Z, SAAD M, ASIM M, et al. The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D[J]. Turk J Gastroenterol, 2020, 31(2): 136-141. DOI: 10.5152/tjg.2020.18846.
[32]	BOGOMOLOV P, ALEXANDROV A, VORONKOVA N, et al. Treatment of chronic hepatitis D with the entry inhibitor Myrcludex B: First results of a phase Ⅰb/Ⅱa study[J]. J Hepatol, 2016, 65(3): 490-498. DOI: 10.1016/j.jhep.2016.04.016.
[33]	WEDEMEYER H, BOGOMOLOV P, BLANK A, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection[J]. J Hepatol, 2018, 68(Suppl 1): S3.
[34]	WEDEMEYER H, SCHÖNEWEIS K, BOGOMOLOV PO, et al. 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection[J]. J Hepatol, 2020, 73(Suppl 1): S52-S53.
[35]	WEDEMEYER H, SCHÖNEWEIS K, BOGOMOLOV PO, et al. GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection[J]. J Hepatol, 2019, 70(Suppl 1): e81.
[36]	GLENN JS, WATSON JA, HAVEL CM, et al. Identification of a prenylation site in delta virus large antigen[J]. Science, 1992, 256(5061): 1331-1333. DOI: 10.1126/science.1598578.
[37]	KOH C, CANINI L, DAHARI H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial[J]. Lancet Infect Dis, 2015, 15(10): 1167-1174. DOI: 10.1016/S1473-3099(15)00074-2.
[38]	YURDAYDIN C, KESKIN O, KALKAN Ç, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study[J]. Hepatology, 2018, 67(4): 1224-1236. DOI: 10.1002/hep.29658.
[39]	WEDEMEYER H, PORT K, DETERDING K, et al. PS-039 - A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the Lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study[J]. J Hepatol, 2017, 66(Suppl 1): S24.
[40]	SHEKHTMAN L, COTLER SJ, HERSHKOVICH L, et al. Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg[J]. Sci Rep, 2020, 10(1): 7837. DOI: 10.1038/s41598-020-64122-0.
[41]	BAZINET M, PÂNTEA V, CEBOTARESCU V, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2017, 2(12): 877-889. DOI: 10.1016/S2468-1253(17)30288-1.
[42]	BAZINET M, PÂNTEA V, CEBOTARESCU V, et al. Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hepatitis B virus/hepatitis delta virus coinfection[J]. Hepatol Commun, 2021, 5(2): 189-202. DOI: 10.1002/hep4.1633.
[43]	YUEN MF, SCHIEFKE I, YOON JH, et al. RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection[J]. Hepatology, 2020, 72(1): 19-31. DOI: 10.1002/hep.31008.
[44]	GANE E, LOCARNINI S, LIM T, et al. Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment[J]. J Hepatol, 2020, 73(Suppl 1): S20.
[45]	JIAO WJ, ZHANG F, AI QG, et al. Study on the treatment of human interferon-α combined with traditional Chinese medicine on HBV/HDV co-infection[J]. Heilongjiang Med Pharm, 1993(4): 11-12. https://www.cnki.com.cn/Article/CJFDTOTAL-HJYY199304010.htm 焦文举, 张甫, 艾钦光, 等. 精制人白细胞α—干扰素配伍中药治疗乙、丁型肝炎病毒重叠感染的研究[J]. 黑龙江医药, 1993(4): 11-12. https://www.cnki.com.cn/Article/CJFDTOTAL-HJYY199304010.htm
[46]	CHEN NL, GU F, JIA KM, et al. Treatment on 26 cases with HBV/HDV co-infection with Xiao Chaihu decoction[J]. Chin J Intern Med, 1990, 29(3): 144-146. 陈乃玲, 顾芳, 贾克明, 等. 小柴胡汤对26例乙型、丁型肝炎重叠感染治疗的探讨[J]. 中华内科杂志, 1990, 29(3): 144-146.
[47]	LIN HH, LEE SS, YU ML, et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program[J]. Hepatology, 2015, 61(6): 1870-1879. DOI: 10.1002/hep.27742.
[48]	SORIANO V, SHERMAN KE, BARREIRO P. Hepatitis delta and HIV infection[J]. AIDS, 2017, 31(7): 875-884. DOI: 10.1097/QAD.0000000000001424.
[49]	SERVANT-DELMAS A, LE GAL F, GALLIAN P, et al. Increasing prevalence of HDV/HBV infection over 15 years in France[J]. J Clin Virol, 2014, 59(2): 126-128. DOI: 10.1016/j.jcv.2013.11.016.
[50]	CHANG SY, YANG CL, KO WS, et al. Molecular epidemiology of hepatitis D virus infection among injecting drug users with and without human immunodeficiency virus infection in Taiwan[J]. J Clin Microbiol, 2011, 49(3): 1083-1089. DOI: 10.1128/JCM.01154-10.
[51]	SHEN DT, HAN PC, JI DZ, et al. Epidemiology estimates of hepatitis D in individuals co-infected with human immunodeficiency virus and hepatitis B virus, 2002-2018: A systematic review and meta-analysis[J]. J Viral Hepat, 2021, 28(7): 1057-1067. DOI: 10.1111/jvh.13512.
[52]	STOCKDALE AJ, KREUELS B, HENRION M, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis[J]. J Hepatol, 2020, 73(3): 523-532. DOI: 10.1016/j.jhep.2020.04.008.
[53]	WANG L, ZHUANG H. Advances in hepatitis D epidemiology[J]. Chin J Viral Dis, 2021, 11(6): 420-426. DOI: 10.16505/j.2095-0136.2021.0053. 王麟, 庄辉. 丁型肝炎流行病学进展[J]. 中国病毒病杂志, 2021, 11(6): 420-426. DOI: 10.16505/j.2095-0136.2021.0053.
[54]	CHEN HY, SHEN DT, JI DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis[J]. Gut, 2019, 68(3): 512-521. DOI: 10.1136/gutjnl-2018-316601.
[55]	FATTOVICH G, BOSCARO S, NOVENTA F, et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B[J]. J Infect Dis, 1987, 155(5): 931-935. DOI: 10.1093/infdis/155.5.931.